AR060543A1 - Composicion que comprende al menos una fase acuosa y al menos una fase grasa que comprende ivermectina - Google Patents

Composicion que comprende al menos una fase acuosa y al menos una fase grasa que comprende ivermectina

Info

Publication number
AR060543A1
AR060543A1 ARP070101680A ARP070101680A AR060543A1 AR 060543 A1 AR060543 A1 AR 060543A1 AR P070101680 A ARP070101680 A AR P070101680A AR P070101680 A ARP070101680 A AR P070101680A AR 060543 A1 AR060543 A1 AR 060543A1
Authority
AR
Argentina
Prior art keywords
phase
compound
ivermectine
composition
fatty phase
Prior art date
Application number
ARP070101680A
Other languages
English (en)
Inventor
Fanny Diaz-Astruc
Nathalie Barthez
Sandrine Segura-Orsoni
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37442024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060543(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of AR060543A1 publication Critical patent/AR060543A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

La presente se refiere a una composicion farmacéutica a base de un compuesto de la familia de las avermectinas que comprende, al menos, una fase grasa y, al menos, una fase acuosa; dicho compuesto de la familia de las avermectinas está disuelto en dicha fase grasa. También se refiere a su procedimiento de preparacion, y a su utilizacion en la fabricacion de una preparacion farmacéutica destinada al tratamiento de las afecciones dermatologicas, en particular, de la rosácea. Reivindicacion 1: Composicion farmacéutica que comprende, al menos, una fase grasa, al menos, una fase acuosa y, al menos, un compuesto de la familia de las avermectinas, caracterizada porque la fase grasa comprende, al menos, un solvente aceitoso distinto de los aceites minerales y vegetales, en el cual está disuelto el compuesto de la familia de las avermectinas.
ARP070101680A 2006-04-19 2007-04-19 Composicion que comprende al menos una fase acuosa y al menos una fase grasa que comprende ivermectina AR060543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0603452A FR2900052B1 (fr) 2006-04-19 2006-04-19 Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine

Publications (1)

Publication Number Publication Date
AR060543A1 true AR060543A1 (es) 2008-06-25

Family

ID=37442024

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101680A AR060543A1 (es) 2006-04-19 2007-04-19 Composicion que comprende al menos una fase acuosa y al menos una fase grasa que comprende ivermectina

Country Status (8)

Country Link
US (2) US8362069B2 (es)
EP (2) EP2010148B1 (es)
JP (1) JP5567329B2 (es)
AR (1) AR060543A1 (es)
BR (1) BRPI0709439A2 (es)
CA (1) CA2648950A1 (es)
FR (1) FR2900052B1 (es)
WO (1) WO2007119028A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
EP2419082B1 (fr) * 2008-12-23 2020-01-22 Galderma S.A. Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
EP2627173B2 (en) 2010-10-12 2018-07-04 Chiesi Farmaceutici S.p.A. Clevidipine emulsion formulations containing antimicrobial agents
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3909586A1 (en) * 2012-06-18 2021-11-17 TherapeuticsMD, Inc. Soluble estradiol capsule for vaginal insertion
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9233118B2 (en) 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US10849854B2 (en) 2015-10-13 2020-12-01 Galderma S.A. Process for preparing a composition comprising a high concentration of one or more avermectins
US11154565B2 (en) 2015-10-13 2021-10-26 Galderma Holding SA Process for preparing a stable emulsion comprising one or more avermectins
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
EP3326609A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
IL307992A (en) 2017-12-15 2023-12-01 Tarsus Pharmaceuticals Inc Parasitic formulations containing isoxazoline and methods for treating blepharitis
CN109964926B (zh) * 2019-04-17 2022-04-19 河北兴柏农业科技有限公司 一种阿维菌素水乳剂及其制备方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN115398224A (zh) * 2020-02-11 2022-11-25 浩思特美容与个人护理创新公司 天然c12-15烷基苯甲酸酯
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL51632C (es) * 1938-02-17
US2778065A (en) * 1951-08-14 1957-01-22 British Rayon Res Ass Method of and means for continuously spreading filaments
US2925628A (en) * 1955-04-25 1960-02-23 Bancroft Brillotex Internat S Machine for separating wool fibres or other filaments
BE573050A (es) * 1957-11-07
US3032829A (en) * 1958-02-11 1962-05-08 Celanese Corp Processing tow
CA674101A (en) * 1961-11-13 1963-11-12 T. Dunlap Donald Tow opening
NL285404A (es) * 1961-11-13 1900-01-01
US3286307A (en) * 1963-09-09 1966-11-22 Celanese Corp Cylindrical banding jets
DE1660266C3 (de) * 1966-03-02 1974-11-14 Deutsche Rhodiaceta Ag, 7800 Freiburg Verfahren und Vorrichtung zum Ausbreiten und Auflockern eines endlosen, laufenden Fadenbündels durch Anblasen mit einem Strömungsmittel
US3795944A (en) * 1971-12-08 1974-03-12 Philco Ford Corp Pneumatic spreading of filaments
US4179776A (en) * 1977-09-19 1979-12-25 Harold Wortman Method and apparatus for deregistering and processing an open synthetic tow into fiber-filled articles
US4559262A (en) * 1981-01-21 1985-12-17 Imperial Chemical Industries, Plc Fibre reinforced compositions and methods for producing such compositions
US5446952A (en) * 1987-12-11 1995-09-05 The United States Of America As Represented By The Secretary Of The Navy Pneumatic induction fiber spreader with lateral venturi restrictors
US5042122A (en) * 1990-02-26 1991-08-27 Board Of Trustees Operating Michigan State University Method and system for spreading a tow of fibers
US5364657A (en) * 1990-04-06 1994-11-15 The University Of Akron Method of depositing and fusing polymer particles onto moistened continuous filaments
DE4026978A1 (de) * 1990-08-25 1992-02-27 Bayer Ag Auf traegern angebrachte ein- oder mehrlagige schichtelemente und ihre herstellung
US5334414A (en) * 1993-01-22 1994-08-02 Clemson University Process for coating carbon fibers with pitch and composites made therefrom
US5518767A (en) * 1993-07-01 1996-05-21 Massachusetts Institute Of Technology Molecular self-assembly of electrically conductive polymers
US6025202A (en) * 1995-02-09 2000-02-15 The Penn State Research Foundation Self-assembled metal colloid monolayers and detection methods therewith
KR100277287B1 (ko) * 1995-09-25 2001-01-15 맨슨 하비 콜린 거대환 락톤 구충제 조성물
GB2310801A (en) * 1996-03-04 1997-09-10 Merck & Co Inc Process for removing an organic solvent from lactide-glycoside copolymer microspheres
US6242264B1 (en) * 1996-09-04 2001-06-05 The Penn State Research Foundation Self-assembled metal colloid monolayers having size and density gradients
US5874093A (en) * 1996-11-15 1999-02-23 Eliaz; Isaac Cosmetic composition containing molecular oxygen
US6114099A (en) * 1996-11-21 2000-09-05 Virginia Tech Intellectual Properties, Inc. Patterned molecular self-assembly
US6507989B1 (en) * 1997-03-13 2003-01-21 President And Fellows Of Harvard College Self-assembly of mesoscale objects
AU9451098A (en) * 1997-10-14 1999-05-03 Patterning Technologies Limited Method of forming an electronic device
JP3740295B2 (ja) * 1997-10-30 2006-02-01 キヤノン株式会社 カーボンナノチューブデバイス、その製造方法及び電子放出素子
US6129901A (en) * 1997-11-18 2000-10-10 Martin Moskovits Controlled synthesis and metal-filling of aligned carbon nanotubes
US6087196A (en) * 1998-01-30 2000-07-11 The Trustees Of Princeton University Fabrication of organic semiconductor devices using ink jet printing
AR018330A1 (es) * 1998-04-27 2001-11-14 Fujisawa Pharmaceutical Co Composiciones farmaceuticas que comprenden macrolidos como agentes activos para la terapia y profilaxis de las enfermedades de la piel
US6649222B1 (en) * 1998-09-07 2003-11-18 The Procter & Gamble Company Modulated plasma glow discharge treatments for making superhydrophobic substrates
US6264741B1 (en) * 1998-11-25 2001-07-24 Sandia Corporation Self-assembly of nanocomposite materials
JP2002535268A (ja) * 1999-01-25 2002-10-22 オプティム セラピューティクス， インコーポレイテッド リポソーム処方物
JP3056200B1 (ja) * 1999-02-26 2000-06-26 鐘淵化学工業株式会社 薄膜光電変換装置の製造方法
AR035550A1 (es) * 1999-06-04 2004-06-16 Nufarm Ltd Composiciones estables biocidas
US6316084B1 (en) * 1999-07-14 2001-11-13 Nanosonic, Inc. Transparent abrasion-resistant coatings, magnetic coatings, electrically and thermally conductive coatings, and UV absorbing coatings on solid substrates
US6447887B1 (en) * 1999-09-14 2002-09-10 Virginia Tech Intellectual Properties, Inc. Electrostrictive and piezoelectric thin film assemblies and method of fabrication therefor
JP2003515438A (ja) * 1999-12-03 2003-05-07 サーロメッド・インコーポレーテッド 金属コロイドナノ粒子のヒドキシルアミン播種
JP3517698B2 (ja) * 2000-03-03 2004-04-12 独立行政法人産業技術総合研究所 ナノ粒子分散構造体及びその積層体
EP1138746B2 (en) * 2000-03-31 2014-01-01 Sumitomo Chemical Company, Limited Polymeric fluorescent substance, production method therof, and polymer light-emitting device using the same
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
AUPQ875700A0 (en) * 2000-07-13 2000-08-03 Reflex Research Limited Combination compositions
GB0025437D0 (en) * 2000-10-17 2000-11-29 Unilever Plc Esters
US6774300B2 (en) * 2001-04-27 2004-08-10 Adrena, Inc. Apparatus and method for photovoltaic energy production based on internal charge emission in a solid-state heterostructure
FR2826672B1 (fr) * 2001-06-29 2003-09-26 Snecma Moteurs Procede et dispositif pour realiser une nappe fibreuse par etalement de cables
DE10134477A1 (de) * 2001-07-16 2003-02-06 Creavis Tech & Innovation Gmbh Selbstreinigende Oberflächen durch hydrophobe Strukturen und Verfahren zu deren Herstellung
DE10140155A1 (de) * 2001-08-16 2003-03-06 Basf Coatings Ag Thermisch sowie thermisch und mit aktinischer Strahlung härtbare Beschichtungsstoffe und ihre Verwendung
PL204021B1 (pl) * 2001-11-02 2009-12-31 Cnt Spo & Lstrok Ka Z Ogranicz Powłoka superhydrofobowa
US7267859B1 (en) * 2001-11-26 2007-09-11 Massachusetts Institute Of Technology Thick porous anodic alumina films and nanowire arrays grown on a solid substrate
EP1540741B1 (en) * 2002-09-05 2014-10-29 Nanosys, Inc. Nanostructure and nanocomposite based compositions and photovoltaic devices
TWI220162B (en) * 2002-11-29 2004-08-11 Ind Tech Res Inst Integrated compound nano probe card and method of making same
US7396569B2 (en) * 2003-02-10 2008-07-08 Nanoscale Materials, Inc. Rapidly self-assembled thin films and functional decals
BRPI0410503B8 (pt) * 2003-04-24 2021-05-25 Galderma Sa composição tópica e uso da composição
FR2862539B1 (fr) * 2003-11-21 2006-03-03 Galderma Res & Dev Utilisation du piketoprofen pour la fabrication d'une composition pharmaceutique pour le traitement de la rosacee
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
US7258731B2 (en) * 2004-07-27 2007-08-21 Ut Battelle, Llc Composite, nanostructured, super-hydrophobic material
US20060024340A1 (en) * 2004-07-30 2006-02-02 Elder Stewart T Encapsulated fluorescent whitening compositions for improved surface appearance
US7309658B2 (en) * 2004-11-22 2007-12-18 Intermolecular, Inc. Molecular self-assembly in substrate processing
WO2006069580A1 (en) * 2004-12-30 2006-07-06 Cheminova A/S Oil-in-water formulation of avermectins
CA2519608A1 (en) * 2005-01-07 2006-07-07 Edward Sargent Quantum dot-polymer nanocomposite photodetectors and photovoltaics
US7261768B2 (en) * 2005-04-07 2007-08-28 Luten Henry A Hydrophobic coatings and methods
US7279085B2 (en) * 2005-07-19 2007-10-09 General Electric Company Gated nanorod field emitter structures and associated methods of fabrication
FR2900052B1 (fr) 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine

Also Published As

Publication number Publication date
WO2007119028A3 (fr) 2008-04-03
EP2010148B1 (fr) 2016-06-29
JP2009534362A (ja) 2009-09-24
EP2374449A2 (fr) 2011-10-12
US8362069B2 (en) 2013-01-29
CA2648950A1 (fr) 2007-10-25
US9592249B2 (en) 2017-03-14
BRPI0709439A2 (pt) 2011-07-05
EP2374449B1 (fr) 2016-01-13
FR2900052A1 (fr) 2007-10-26
EP2010148A2 (fr) 2009-01-07
US20090136574A1 (en) 2009-05-28
EP2374449A3 (fr) 2012-02-29
JP5567329B2 (ja) 2014-08-06
US20130108563A1 (en) 2013-05-02
WO2007119028A9 (fr) 2009-01-15
FR2900052B1 (fr) 2011-02-18
WO2007119028A2 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
AR060543A1 (es) Composicion que comprende al menos una fase acuosa y al menos una fase grasa que comprende ivermectina
BRPI0508167A (pt) composição farmacêutica, seu processo de preparação e seu uso
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
DOP2007000102A (es) Arilimidazolonas y ariltriazolona sustituidas asi como su uso
CR7999A (es) Metodos y composiciones farmaceuticas para la obtencion confiable de niveles aceptables de testosterona en suero
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
HN2009000784A (es) Dihidropirazolonas sustituidas
AR109263A2 (es) Composición que comprende moxidectina
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CL2007003630A1 (es) Composicion farmaceutica que comprende vitamina c, vitamina e, luteina, zinc, acido graso omega-3 y cobre; metodo de elaboracion; y uso para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad (amd) y/o retinopatia diabet
CL2011002268A1 (es) Uso de compuestos derivados de acidos grasos poliinsaturados para el tratamiento de enfermedades neurodegenerativas y neurologicas; y composicion farmaceutica o nutraceutica.
AR054255A1 (es) Tratamiento de la disfuncion intestinal enpacientes con hiv
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
AR074841A1 (es) Composicion que comprende aceite de canamo para tratar enfermedades topicas, especialmente el sindrome mano-pie
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
UY30424A1 (es) Derivados de quinolina, su preparacion, su uso y medicamentos que comprenden los mismos.
CL2014001711A1 (es) Metodo para enmascarar el olor de un semioquimico de pez en el agua, que comprende añadir un extracto de lavanda a dicha agua o se administra a un pez en dicha agua; metodo para reducir la atraccion entre un parasito y un pez; composicion de alimento; y uso de extracto de lavanda (divisional solicitud 1434-12).
WO2008013669A3 (en) Alpha hydroxy acid sustained release formulation
ES2669311T3 (es) Incremento de la biodisponibilidad de los ácidos hidroxicinámicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal